Teva Pharma (TEVA) Sues FDA to Block Generic Copaxone (MYL)
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
(Updated - May 9, 2014 2:34 PM EDT)
Teva Pharma (NYSE: TEVA) sued the U.S. FDA over generic COPAXONE.
In March, Teva announced that the U.S. Supreme Court has granted the Company’s COPAXONE certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808. The 808 patent expires on September 1, 2015 and claims a process for manufacturing the active ingredient of Teva’s relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE (glatiramer acetate injection) 20mg/mL.
The Supreme Court later rejected Teva's move to block generic versions of COPAXONE in the appeal.
With the latest suit, Teva claims that the FDA is failing to respond to a request for generic trials.
On watch today also includes Mylan Inc. (Nasdaq: MYL). Teva is down 2 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novan (NOVN) Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
- Avita Medical Limited (RCEL) Announces FDA Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients
- Equillium (EQ) Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
Create E-mail Alert Related CategoriesFDA, Hot Corp. News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!